Eagle Pharmaceuticals (NASDAQ:EGRX) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a report released on Tuesday.

According to Zacks, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. “

A number of other brokerages have also issued reports on EGRX. ValuEngine raised Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. BidaskClub raised Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, December 2nd. Mizuho reissued a “sell” rating and issued a $37.00 price objective on shares of Eagle Pharmaceuticals in a report on Wednesday, November 8th. Royal Bank of Canada reissued an “outperform” rating and issued a $75.00 price objective (down from $81.00) on shares of Eagle Pharmaceuticals in a report on Thursday, November 9th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $75.00 price objective on shares of Eagle Pharmaceuticals in a report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $62.33.

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) traded up $0.60 during mid-day trading on Tuesday, reaching $59.44. The company had a trading volume of 107,000 shares, compared to its average volume of 187,186. Eagle Pharmaceuticals has a 1-year low of $45.05 and a 1-year high of $97.15. The company has a market cap of $890.30, a price-to-earnings ratio of 9.57 and a beta of 1.24. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.30 and a quick ratio of 5.15.

A number of hedge funds have recently modified their holdings of the stock. Schwab Charles Investment Management Inc. boosted its stake in Eagle Pharmaceuticals by 2.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 37,053 shares of the specialty pharmaceutical company’s stock valued at $2,924,000 after purchasing an additional 737 shares in the last quarter. First Trust Advisors LP bought a new position in Eagle Pharmaceuticals during the 2nd quarter valued at $1,989,000. State of Wisconsin Investment Board bought a new position in Eagle Pharmaceuticals during the 2nd quarter valued at $473,000. Bank of New York Mellon Corp boosted its stake in Eagle Pharmaceuticals by 0.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 116,510 shares of the specialty pharmaceutical company’s stock valued at $9,191,000 after purchasing an additional 482 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in Eagle Pharmaceuticals by 3.9% during the 2nd quarter. Legal & General Group Plc now owns 14,984 shares of the specialty pharmaceutical company’s stock valued at $1,182,000 after purchasing an additional 563 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: “Eagle Pharmaceuticals (EGRX) Stock Rating Lowered by Zacks Investment Research” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://theolympiareport.com/2018/01/11/eagle-pharmaceuticals-egrx-stock-rating-lowered-by-zacks-investment-research.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.